<div id="readability-page-1"><p>MFG Wealth Management Inc. bought a new position in  AbbVie Inc. (NYSE:ABBV - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 6,431 shares of the company's stock, valued at approximately $1,489,000.</p><ul><li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li></ul><p>Several other hedge funds have also modified their holdings of ABBV. TD Capital Management LLC boosted its position in  AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after buying an additional 58 shares during the last quarter.  Marshall &amp; Sullivan Inc. WA acquired a new position in shares of  AbbVie in the 2nd quarter valued at $25,000.  Evolution Wealth Management Inc. bought a new position in shares of  AbbVie in the 2nd quarter worth $26,000.  Spurstone Advisory Services LLC acquired a new stake in shares of  AbbVie during the second quarter worth $28,000.  Finally, Financial Gravity Companies Inc. bought a new stake in  AbbVie in the second quarter valued at about $36,000. 70.23% of the stock is owned by institutional investors. </p><h2>AbbVie Stock Up 2.1%</h2><p>Shares of AbbVie stock opened at $227.44 on Friday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market cap of $401.98 billion, a PE ratio of 172.30, a P/E/G ratio of 1.27 and a beta of 0.36. The business's 50 day simple moving average is $226.63 and its 200 day simple moving average is $210.98. </p><ul><li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to analysts' expectations of $15.58 billion. During the same quarter in the prior year, the company posted $3.00 earnings per share. The firm's revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.  On average, analysts predict that  AbbVie Inc. will post 12.31 earnings per share for the current fiscal year. </p><h2>AbbVie Increases Dividend</h2><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. This is a boost from AbbVie's previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie's payout ratio is currently 496.97%. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>ABBV has been the subject of several analyst reports. Scotiabank initiated coverage on AbbVie in a research report on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $280.00 target price for the company. Raymond James Financial  set a $256.00 price objective on shares of AbbVie in a research note on Monday, November 3rd. Wall Street Zen raised shares of AbbVie from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, December 13th. Evercore ISI increased their target price on shares of AbbVie from $207.00 to $222.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday, September 22nd. Finally, UBS Group boosted their price target on shares of AbbVie from $195.00 to $220.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, November 7th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned  a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $245.84.</p><p><b>View Our Latest Research Report on AbbVie</b></p><h2>About AbbVie</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than AbbVie</li><li>3 Stocks to Consider Buying in October</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>What is a buyback in stocks? A comprehensive guide for investors</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li><li>5 Top Rated Dividend Stocks to Consider</li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li></ul><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>MFG Wealth Management Inc. acquired 6,431 shares of AbbVie Inc. (NYSE:ABBV) in the third quarter, valued at approximately $1,489,000. AbbVie reported Q3 earnings of $1.86 per share, beating estimates, with revenue of $15.78 billion. The company increased its quarterly dividend to $1.73 per share. Analysts have given AbbVie a consensus rating of 'Moderate Buy' with an average target price of $245.84.</p>

MFG Wealth Management Inc. Acquires Shares of 6,431 AbbVie Inc. $ABBV